A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells

Anna Vert; Jessica Castro; Marc Ribó; Antoni Benito; Maria Vilanova

doi:10.18632/oncotarget.7579

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells

Anna Vert, Jessica Castro, Marc Ribó, Antoni Benito and Maria Vilanova _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:18309-18324. https://doi.org/10.18632/oncotarget.7579

Metrics: PDF 2011 views | HTML 3500 views | ?

Abstract

Anna Vert1,2, Jessica Castro1,2, Marc Ribó1,2, Antoni Benito1,2, Maria Vilanova1,2

1Laboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Universitat de Girona, Girona, Spain

2Institut d’Investigació Biomèdica de Girona Josep Trueta, (IdIBGi), Girona, Spain

Correspondence to:

Maria Vilanova, email: [email protected]

Antoni Benito, email: [email protected]

Keywords: antitumor drug, human pancreatic ribonuclease, metabolism of cancer cells, microarray profiling, tumor cell death

Received: December 18, 2015 Accepted: February 11, 2016 Published: February 22, 2016

ABSTRACT

Ribonucleases represent a new class of antitumor RNA-damaging drugs. However, many wild-type members of the vertebrate secreted ribonuclease family are not cytotoxic because they are not able to evade the cytosolic ribonuclease inhibitor. We previously engineered the human pancreatic ribonuclease to direct it to the cell nucleus where the inhibitor is not present. The best characterized variant is PE5 that kills cancer cells through apoptosis mediated by the p21^WAF1/CIP1 induction and the inactivation of JNK. Here, we have used microarray-derived transcriptional profiling to identify PE5 regulated genes on the NCI/ADR-RES ovarian cancer cell line. RT-qPCR analyses have confirmed the expression microarray findings. The results show that PE5 cause pleiotropic effects. Among them, it is remarkable the down-regulation of multiple genes that code for enzymes involved in deregulated metabolic pathways in cancer cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7579

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells

Abstract